Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2276-2284

  Speetjens, Frank M ^a   Kuppen, Peter J K ^a   Sandel, Maro H ^a   Menon, Anand G ^a   Burg, Danny ^b   Van DeVelde, Cornelis J H ^a   Tollenaar, Rob A E M ^a   De Bont, Hans J G M ^b   Nagelkerke, J Fred ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE DISRUPTION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; TUMOR GROWTH;

AGED; ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL5; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROGNOSIS; RATS;

EID: 42249100669     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4045     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
3. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum1997;40:15-24.
4. Velthuis JH, Stitzinger M, Aalbers RI, et al. Rat colon carcinoma cells that survived systemic immune surveillance are less sensitive to NK-cell mediated apoptosis. Clin Exp Metastasis 2003;20:713-21.
5. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment ofa transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984;33:689-92.
6. Chandrasekar B, Melby PC, Sarau HM, et al. Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-κB pathway. J Biol Chem 2003;278:4675-86.
7. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005;16:593-609.
8. Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996;271:20545-50.
9. Persson T, Monsef N, Andersson P, et al. Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy 2003;33:531-7.
10. Lippert U, Zachmann K, Henz BM, Neumann C. Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2. Exp Dermatol 2004;13:520-5.
11. Keates S, Keates AC, Mizoguchi E, Bhan A, Kelly CP. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol 1997;273:G75-82.
12. Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int JOncol 2007;31:97-102.
13. Park JY, Park KH, Bang S, et al. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 2007;133:835-40.
14. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998;102:465-72.
15. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006;66:4279-84.
16. Fidler IJ, Caines S, Dolan Z. Survival of hematogenously disseminated allogeneic tumor cells in athymic nude mice. Transplantation 1976;22:208-12.
17. Imamdi R, de Graauw M, van de WB. Protein kinase C mediates cisplatin-induced loss of adherens junctions followed by apoptosis of renal proximal tubular epithelial cells. J Pharmacol Exp Ther 2004;311:892-903.
18. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-κB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 2001;103:2296-302.
19. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem1990;191:31-4.
20. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966;36:641-5.
21. van Duijnhoven FH, Aalbers RI, Rothbarth J, Terpstra OT, Kuppen PJ. A systemic antitumor immune response prevents outgrowth of lung tumors after i.v. rechallenge but is not able to prevent growth of experimental liver tumors. Clin Exp Metastasis 2004;21:13-8.
22. Treanor D, Quirke P. Pathology of colorectal cancer. Clin Oncol (R Coll Radiol) 2007;19:769-76.
23. Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493-501.
24. Gijsbers K, Geboes K, Van Damme J. Chemokines in gastrointestinal disorders. Curr Drug Targets 2006;7:47-64.
25. Keates AC, Keates S, Kwon JH, et al. ZBP-89, Sp1, and nuclear factor-κB regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 2001;276:43713-22.
26. Ho KK, Auld DS, Bohnstedt AC, et al. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett 2006;16:2724-8.
27. Casilli F, Bianchini A, Gloaguen I, et al. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol 2005;69:385-94.
28. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002;71:173-83.
29. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
30. Naito Y, Saito K, Shiiba K, et al. CD8+ Tcells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
31. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189:487-95.
32. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
33. van Deventer HW, Serody JS, McKinnon KP, Clements C, Brickey WJ, Ting JP. Transfection of macrophage inflammatory protein 1 α into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. J Immunol 2002;169:1634-9.
34. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of themouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
35. Gao JQ, Sugita T, Kanagawa N, et al. Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. Biol Pharm Bull 2005;28:1066-70.
36. Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89:1-7.
37. Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and Tcells. Eur J Immunol 2005;35:1371-80.
38. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007;109:2392-404.
39. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M, Kitano S. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J Gastroenterol Hepatol 2007;22:690-6.
40. Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67:4725-31.
41. Williams EJ, Haque S, Banks C, Johnson P, Sarsfield P, Sheron N. Distribution of the interleukin-8 receptors, CXCR1 and CXCR2, in inflamed gut tissue. J Pathol 2000;192:533-9.
42. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001;7:3298-304.
43. Li A, Varney ML, Singh RK. Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clin Exp Metastasis 2004;21:571-9.
44. Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer Res 2006;66:7405-13.
45. Wente MN, Keane MP, Burdick MD, et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006;241:221-7.